FindTrial
Sign In

Study on the mechanism of immunosuppression through Galectin-3 express of breast cancer cells

Study on the mechanism of immunosuppression through Galectin-3 express of breast cancer cells

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-12001919
Enrollment
Unknown
Registered
2012-02-02
Start date
2011-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Case series:Nil

Sponsors

Nanjing Maternity and Child Health Hospital of Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 82 Years

Inclusion criteria

Inclusion criteria: breast cancer

Exclusion criteria

Exclusion criteria: Other tumors expect breast cancer

Design outcomes

Primary

MeasureTime frame
Galectin-3;—

Countries

China

Contacts

Public ContactHong Yin
yy787832@163.com+86 025 52226265

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026